Replies to post #223849 on Biotech Values

[mcbio]

NITE/(AGTC) -

BIIB acquires NITE for $25.50/sh cash—a 68% premium to Friday’s close

Presumably another red flag for AGTC in that BIIB would move so quickly from their former partnership with AGTC to outright acquiring a direct competitor in the eye GT space.

[DewDiligence]

BIIB gene-therapy drug acquired in NITE buyout fails phase-2/3 trial in XLRP:

https://finance.yahoo.com/news/biogen-announces-topline-results-phase-113000443.html